Evaluation of PSMA-PET and mpMRI in high-risk prostate cancer – using histopathologic validation - PAMP2

Region Vasterbotten0 个研究点目标入组 20 人开始时间: 2023年12月20日最近更新: 2024年7月22日

适应症

试验速览

暂无简介。

•Histologically confirmed high-risk prostate cancer planned to be treated with radical prostatectomy, PSMA-PET/CT conducted as part of the clinical management for the existing prostate cancer, =4 weeks since last biopsy of the prostate, One or more of the following criteria: a) cT3, or high suspicion of extra prostatic growth on mpMRI b) Gleason score =8 c) PSA 20-49 ng/ml, >18 years, Given a written consent to participate in the trial

•Non-MR-safe implants or another contraindication to MRI or PET, Tinnitus or severe hearing loss, Claustrophobia, Unfit for MRI or PET/MRI examination for any other reason, e.g., back pain, WHO PS >1, Patients treated with neoadjuvant/concomitant anti-testosterone treatment (surgical or medical castration such or anti-androgens), TUR-P within 6 months, Metastatic disease in skeleton, parenchymal organs, or lymph nodes outside the pelvis., Patients with previous diagnosis of other malignant disease. Exceptions could be made for basal cell carcinoma of the skin or progression free survival at least 10 years after any previous tumor., Creatinine clearance < 30ml/min

发起方

Region Vasterbotten